UniQure Plans Tests That Could Lead to Clinical Trial of AMT-130 Gene Therapy for Huntington’s – Huntington’s Disease News
|
UniQure Plans Tests That Could Lead to Clinical Trial of AMT-130 Gene Therapy for Huntington's
Huntington’s Disease News Dutch pharmaceutical company uniQure says it plans to conduct preclinical studies leading to clinical testing of a gene therapy in patients with Huntington's disease. The company is developing AMT-130, an experimental therapy that aims to block … |
